急性心肌梗死患者循环血清mircoRNAs表达的研究

季倩; 田玉龙; 李小波; 张瑶俊; 孟培娜; 邵明学; 陈立文; 朱灏; 田

doi:10.13201/j.issn.1001-1439.2015.08.013

急性心肌梗死患者循环血清mircoRNAs表达的研究

- 1. 南京医科大学附属南京医院心内科南京市第一医院(南京, 210000);
- 2. 江苏省盱眙县人民医院心内科

详细信息

通讯作者: 田乃亮,E-mail:tiannailiang@163.com

中图分类号: R542.2

收稿日期: 2014-11-17

修回日期: 2015-03-06

Expression of circulating mircoRNAs in patients with acute myocardial infarction

- 1. Department of Cardiology, Nanjing First Hospital Nanjing University, Nanjing, 210000, China;
- 2. Department of Cardiology, Xuyi People's Hospital

More Information

Corresponding author: TIAN Nailiang, E-mail: tiannailiang@163.com

Received Date: 17 November 2014

Revised Date: 06 March 2015

摘要

摘要: 目的：探讨循环血清microRNAs与急性心肌梗死（AMI）的相关性，分析其在早期诊断AMI中的价值。方法：选取2013-10-2014-08于我院心内科住院诊治的AMI患者，其中ST段抬高型心肌梗死（STEMI）患者77例（STEMI组），非ST段抬高型心肌梗死（NSTEMI）患者21例（NSTEMI组），以及同期体检的23名健康人群做对照（对照组），通过实时荧光定量聚合酶链反应（qRT-PCR）检测血清中miR-133a、miR-133b、miR-499-5p的含量，同时采用酶联免疫吸附法（ELISA）检测血cTnI的含量并分析其与AMI的相关性。结果：STEMI组和NSTEMI组患者血清miR-133a、miR-133b、miR-499-5p水平较对照组明显升高（均P<0.05）。1~4 h组血清miR-133a、miR-133b、miR-499-5p表达量较5~12 h组和13~24 h组明显升高（均P<0.05）。此外，受试者工作特征曲线（ROC曲线）分析显示，miR-133a、miR-133b、miR-499-5p在诊断AMI方面具有明确的特异性和敏感性，但并不优于cTnI。结论：血清miR-133a、miR-133b、miR-499-5p可作为新型的早期诊断AMI的标记物，但并不优于cTnI。
- 循环microRNAs /
- 急性心肌梗死
Abstract: Objective: To investigate MicroRNA expression in ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation myocardial infarction (NSTEMI), and to compare their diagnostic values.Method: We assessed 77 STEMI and 21 NSTEMI patients admitted to the Department of Cardiology in Nanjing First Hospital from October 2013 to August 2014. And 23 healthy volunteers were selected at the same time. Serum miR-133a、miR-133b and miR-499-5p were quantified by using quantitative reverse transcriptase-polymerase chain reaction (qRT-PCR), and the concentration of serum cTnI was measured using enzyme-linked immunosorbent assay (ELISA) methods.Result: The level of miR-133a、miR-133b and miR-499-5p were significantly higher in both STEMI and NSTEMI patients compared to healthy volunteers(P<0.05), and were significantly increased in the early phase (the first 4 hours)(P<0.05). Furthermore, receiver operating characteristic (ROC) curve analyses showed that miR-133a、miR-133b and miR-499-5p were specific and sensitive for the diagnosis of AMI, but not superior to cTnI.Conclusion: Serum miR-133a、miR-133b and miR-499-5p might be used as a biomarker but is not superior to cTnI for early diagnosis of AMI.
- circulating mircoRNA /
- acute myocardial infarction

HTML全文

参考文献(20)

[1]	BARTEL D P. MicroRNAs:genomics, biogenesis, mechanism, and function[J]. Cell, 2004, 116:281-297.
[2]	DE ROSA S, FICHTLSCHERER S, LEHMANN R, et al. Transcoronary concentration gradients of circulating microRNAs[J]. Circulation, 2011, 124:1936-1944.
[3]	WANG R, LI N, ZHANG Y, et al. Circulating microRNAs are promising novel biomarkers of acute myocardial infarction[J]. Intern Med, 2011;50:1789-1795.
[4]	D'ALESSANDRA Y, DEVANNA P, LIMANA F, et al. Circulating microRNAs are new and sensitive biomarkers of myocardial infarction[J]. Eur Heart J, 2010, 31:2765-2773.
[5]	WIDERA C, GUPTA S K, LORENZEN J M, et al. Diagnostic and prognostic impact of six circulating microRNAs in acute coronary syndrome[J]. J Mol Cell Cardiol, 2011, 51:872-875.
[6]	GIDLOF O, ANDERSSON P, VAN DER PALS J, et al. Cardiospecific microRNA plasma levels correlate with troponin and cardiac function in patients with st elevation myocardial infarction, are selectively dependent on renal elimination, and can be detected in urine samples[J]. Cardiology, 2011, 118:217-226.
[7]	KUWABARA Y, ONO K, HORIE T, et al. Increased microRNA-1 and microRNA-133a levels in serum of patients with cardiovascular disease indicate myocardial damage[J]. Circ Cardiovasc Genet, 2011, 4:446-454.
[8]	OLIVIERI F, ANTONICELLI R, LORENZI M, et al. Diagnostic potential of circulating miR-499-5p in elderly patients with acute non ST-elevation myocardial infarction[J]. Int J Cardiol, 2012, 167, 531-536.
[9]	FICHTLSCHERER S, DE ROSA S, FOX H, et al. Circulating microRNAs in patients with coronary artery disease[J]. Circ Res, 2010, 107:677-684.
[10]	TIJSEN A J, CREEMERS E E, MOERLAND P D, et al. MiR423-5p as a circulating biomarker for heart failure[J]. Circ Res, 2010, 106:1035-1039.
[11]	MITCHELL P S, PARKIN R K, KROH E M, et al.Circulating microRNAs as stable blood-based markers for cancer detection[J]. Proc Natl Acad Sci U S A, 2008, 105:10513-10518.
[12]	GILAD S, MEIRI E, YOGEV Y, et al. Serum microRNAs are promising novel biomarkers[J]. PLoS One, 2008, 3:e3148.
[13]	HAN M, TOLI J, ABDELLATIF M. MicroRNAs in the cardiovascular system[J]. Curr Opin Cardiol, 2011, 26:181-189.
[14]	TORELLA D, IACONETTI C, CATALUCCI D, et al. MicroRNA-133 controls vascular smooth muscle cell phenotypic switch in vitro and vascular remodeling in vivo[J]. Circ Res, 2011, 109:880-893.
[15]	SHIEH J T, HUANG Y, GILMORE J, et al. Elevated miR-499 levels blunt the cardiac stress response[J]. PLoS One, 2011, 6:e19481.
[16]	VAN ROOIJ E, QUIAT D, JOHNSON B A, et al. A family of microRNAs encoded by myosin genes governs myosin expression and muscle performance[J]. Dev Cell, 2009, 17:662-673.
[17]	KIM H J, CUI X S, KIM E J, et al. New porcine microRNA genes found by homology search[J]. Genome, 2006, 49:1283-1286.
[18]	WANG J X, JIAO J Q, LI Q, et al. miR-499 regulates mitochondrial dynamics by targeting calcineurin and dynamin-related protein-1[J]. Nat Med, 2011, 17:71-78.
[19]	CORSTEN M F, DENNERT R, JOCHEMS S, et al. Circulating microRNA-208b and microRNA-499 reflect myocardial damage in cardiovascular disease[J]. Circ Cardiovasc Genet, 2010, 3:499-506.
[20]	WANG G K, ZHU J O, ZHANG J T, et al. Circulating microRNA:a novel potential biomarker for early diagnosis of acute myocardial infarction in humans[J]. Eur Heart J, 2010, 31:659-666.